Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$30.1 million.

  • GeneDx Holdings' Cash from Investing Activities rose 39.56% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year decrease of 47.82%. This contributed to the annual value of -$30.1 million for FY2024, which is 31.09% up from last year.
  • As of FY2024, GeneDx Holdings' Cash from Investing Activities stood at -$30.1 million, which was up 31.09% from -$43.7 million recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' Cash from Investing Activities registered a high of -$20.8 million during FY2021, and its lowest value of -$141.3 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$71.7 million, with a median of -$43.7 million in 2023.
  • As far as peak fluctuations go, GeneDx Holdings' Cash from Investing Activities crashed by 579.91% in 2022, and later soared by 69.06% in 2023.
  • Yearly analysis of 5 years shows GeneDx Holdings' Cash from Investing Activities stood at -$32.0 million in 2020, then spiked by 34.99% to -$20.8 million in 2021, then tumbled by 579.91% to -$141.3 million in 2022, then soared by 69.06% to -$43.7 million in 2023, then skyrocketed by 31.09% to -$30.1 million in 2024.